Posted by Michael Wonder on 31 Jan 2024
GSK Canada's submission for momelotinib for the treatment of myelofibrosis accepted for review by Health Canada
30 January 2024 - GSK announces that Heath Canada has accepted into review the new drug submission for momelotinib, a potential new medicine with a differentiated mechanism of action that may help address the significant medical needs of myelofibrosis patients, especially those with anaemia.
The new drug submission is based on key Phase 3 trials SIMPLIFY-1 and MOMENTUM.
